Commercial milestones payments receivable.

No definition available.

Name:	scyx_CommercialMilestonesPaymentsReceivable
Namespace Prefix:	scyx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Development milestones receivable.

+ References

No definition available.

+ Details

Name:	scyx_DevelopmentMilestonesReceivable
Namespace Prefix:	scyx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Development milestones recevied.

+ References

No definition available.

+ Details

Name:	scyx_DevelopmentMilestonesRecevied
Namespace Prefix:	scyx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement contract asset.

+ References

No definition available.

+ Details

Name:	scyx_LicenseAgreementContractAsset
Namespace Prefix:	scyx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License agreement receivable.

+ References

No definition available.

+ Details

Name:	scyx_LicenseAgreementReceivable
Namespace Prefix:	scyx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Regulatory milestone payments receivable.

+ References

No definition available.

+ Details

Name:	scyx_RegulatoryMilestonePaymentsReceivable
Namespace Prefix:	scyx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Sales milestone payable upon achievement of threshold limit.

+ References

No definition available.

+ Details

Name:	scyx_SalesMilestonePayableUponAchievementOfThresholdLimit
Namespace Prefix:	scyx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Sales milestone payments receivable

+ References

No definition available.

+ Details

Name:	scyx_SalesMilestonePaymentsReceivable
Namespace Prefix:	scyx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_DeferredRevenueNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=scyx_GlaxosmithklineIntellectualPropertyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=scyx_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=scyx_LicenseTransferMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=scyx_ExclusiveLicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=scyx_AchivementOfThresholdUpto200MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	scyx_RelaunchDateAxis=scyx_RelaunchDateOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	scyx_RelaunchDateAxis=scyx_RelaunchDateTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	scyx_RelaunchDateAxis=scyx_RelaunchDateThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=scyx_AchivementOfThresholdUpto300MillionTo500MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=scyx_AchivementOfThresholdUpto750MillionTo1BillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=scyx_SuccessfulCompletionOfMarioStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=scyx_CompletionFuriCaresAndNatureClinicalStudiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=scyx_AchivementOfTwoInterimMilestoneOfOngoingMarioStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=scyx_WholesalerOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=scyx_WholesalerTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=scyx_WholesalerThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue - Additional Information (Detail) - USD ($)			1 Months Ended	3 Months Ended
Revenue - Additional Information (Detail) - USD ($)	Dec. 26, 2023	Mar. 30, 2023	Jun. 30, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Disaggregation Of Revenue [Line Items]
Net product revenue				$ 1,373,000	$ 1,130,000
License agreement receivable				0		$ 2,463,000
Deferred revenue, current portion				1,083,000		1,189,000
Deferred revenue, long term				2,111,000		$ 2,727,000
Product Revenue, Net
Disaggregation Of Revenue [Line Items]
Net product revenue				0	1,130,000
GlaxoSmithKline Intellectual Property
Disaggregation Of Revenue [Line Items]
License agreement contract asset				19,500,000
License Agreement \| GlaxoSmithKline Intellectual Property
Disaggregation Of Revenue [Line Items]
Development milestones recevied			$ 25,000,000
License Agreement \| GlaxoSmithKline Intellectual Property \| License Transfer
Disaggregation Of Revenue [Line Items]
Revenue recognized				1,400,000
Exclusive License And Collaboration Agreement
Disaggregation Of Revenue [Line Items]
Revenue recognized				$ 0	$ 0
Achivement of Threshold Upto 200 Million \| License Agreement \| GlaxoSmithKline Intellectual Property \| Relaunch Date One
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	$ 64,000,000
Achivement of Threshold Upto 200 Million \| License Agreement \| GlaxoSmithKline Intellectual Property \| Relaunch Date Two
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	54,250,000
Achivement of Threshold Upto 200 Million \| License Agreement \| GlaxoSmithKline Intellectual Property \| Relaunch Date Three
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	46,500,000
Achivement of Threshold Upto 300 million to 500 Million \| License Agreement \| GlaxoSmithKline Intellectual Property \| Relaunch Date One
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	45,500,000
Achivement of Threshold Upto 300 million to 500 Million \| License Agreement \| GlaxoSmithKline Intellectual Property \| Relaunch Date Two
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	45,500,000
Achivement of Threshold Upto 300 million to 500 Million \| License Agreement \| GlaxoSmithKline Intellectual Property \| Relaunch Date Three
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	39,000,000
Achivement of Threshold Upto 750 million to 1 Billion \| License Agreement \| GlaxoSmithKline Intellectual Property \| Relaunch Date One
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	35,000,000
Achivement of Threshold Upto 750 million to 1 Billion \| License Agreement \| GlaxoSmithKline Intellectual Property \| Relaunch Date Two
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	35,000,000
Achivement of Threshold Upto 750 million to 1 Billion \| License Agreement \| GlaxoSmithKline Intellectual Property \| Relaunch Date Three
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	30,000,000
Successful Completion of Mario Study \| License Agreement \| GlaxoSmithKline Intellectual Property
Disaggregation Of Revenue [Line Items]
Development milestones recevied	7,350,000
Completion FURI, CARES, and NATURE Clinical Studies \| License Agreement
Disaggregation Of Revenue [Line Items]
Development milestones recevied	10,000,000
Maximum \| License Agreement \| GlaxoSmithKline Intellectual Property
Disaggregation Of Revenue [Line Items]
Regulatory milestone payments receivable	49,000,000	$ 70,000,000
Commercial milestones payments receivable	57,500,000	115,000,000
Sales milestone payments receivable		242,500,000
Development milestones receivable	72,350,000	$ 75,500,000
Maximum \| License Agreement \| GlaxoSmithKline Intellectual Property \| Relaunch Date One
Disaggregation Of Revenue [Line Items]
Sales milestone payments receivable	179,500,000
Maximum \| License Agreement \| GlaxoSmithKline Intellectual Property \| Relaunch Date Two
Disaggregation Of Revenue [Line Items]
Sales milestone payments receivable	169,750,000
Maximum \| License Agreement \| GlaxoSmithKline Intellectual Property \| Relaunch Date Three
Disaggregation Of Revenue [Line Items]
Sales milestone payments receivable	145,500,000
Maximum \| Achivement of Two Interim Milestone of Ongoing Mario Study \| License Agreement \| GlaxoSmithKline Intellectual Property
Disaggregation Of Revenue [Line Items]
Development milestones receivable	$ 30,000,000
Sales Revenue Net \| Customer Concentration Risk \| Wholesaler One
Disaggregation Of Revenue [Line Items]
Percentage of gross revenue					46.00%
Sales Revenue Net \| Customer Concentration Risk \| Wholesaler Two
Disaggregation Of Revenue [Line Items]
Percentage of gross revenue					26.00%
Sales Revenue Net \| Customer Concentration Risk \| Wholesaler Three
Disaggregation Of Revenue [Line Items]
Percentage of gross revenue					25.00%